FDA saddles Orexigen with weighty data demand

One year's data is not enough. Orexigen Therapeutics has started laying off 40 percent of staff following FDA's override of an expert panel endorsement and rejection of its obesity treatment application. Additional cardiovascular data required could take two years and $200 million to collect. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.